



MATINS
HEALTHCARE PVT. LTD.

MATINS HEALTHCARE PVT. LTD.

PLOT No - 10, SEC TOR-5, IIE, SIDCUL, HARIDWAR
Mfg. Licence No.: 61/UA/SC/P-2006 & 62/UA/2006

QUALITY CONTROL DEPARTMENT (FINISHED)

(The Drugs & Cosmetics Act 1940 and the Rules there under)

CERTIFICATE OF ANALYSIS

Product Name	HEALMARYL MV 2.3	A.R. No.	MFGT-231280
Generic Name	Voglibose, Glimepiride & Metformin Hydrochloride (SR) Tablets	Batch Size	1.0 Lac Tablets
Batch No.	MT-231280	Sample Qty.	100 Tablets
Mfg. Date	10/2023	Sample received date	25/11/2023
Exp. Date	09/2025	Date of Release	27/11/2023
Sr. No.	TESTS	SPECIFICATIONS	RESULTS
1	Description	Pink/White colour elongated, biconvex, uncoated bilayer tablets	Pink/White colour elongated, biconvex, uncoated bilayer tablets
2	Identification: By HPLC	The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay.	Complies
3	Average weight	850 mg $\pm$ 5% (807.5 to 892.5 mg)	848.20 mg
4	Uniformity of weight	$\pm$ 5% on average weight	Positive deviation= 2.28% Negative deviation= 2.39%
5	Uniformity of content for Glimepiride	NLT 85% to NMT 115%	92.36% to 98.89%
6	Uniformity of content for Voglibose	NLT 85% to NMT 115%	94.13% to 99.92%
7	Dissolution for Metformin Hydrochloride After 1 st hour After 3 rd hour After 10 th hour	(NMT 40%) (45% to 75%) (NLT 85%)	(30.21% to 37.31%) (60.35% to 70.26%) (92.57% to 99.38%)
8	Assay: Each uncoated bilayer tablet contains:		
	Metformin Hydrochloride IP 500 mg (As Sustained release)	Not less than 90% and not more than 110% (450.0 mg to 550.0 mg)	510.17 mg (102.03%)
	Glimepiride IP 2 mg	Not less than 90% and not more than 110% (1.8 mg to 2.2 mg)	1.98 mg (99.00%)
	Voglibose IP 0.3 mg	Not less than 90% and not more than 110% (0.27 mg to 0.33 mg)	0.302 mg (100.67%)

Remarks: The product complies as per IHS Specification.

On
27/11/2023
Analyzed by

X
27/11/2023
Checked by

